MESO (Mesoblast) Institutional Ownership : 2.62% (As of Mar. 14, 2025)

View and export this data going back to 2010. Start your Free Trial

What is Mesoblast Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mesoblast's institutional ownership is 2.62%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mesoblast's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mesoblast's Float Percentage Of Total Shares Outstanding is 79.63%.

Mesoblast Institutional Ownership Historical Data

The historical data trend for Mesoblast's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Institutional Ownership Chart

Mesoblast Historical Data

The historical data trend for Mesoblast can be seen below:

	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31
Institutional Ownership	0.06	0.06	0.06	0.02	0.02	0.02	0.02	0.02	0.55	0.54

Mesoblast Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (NAS:MESO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MEOBF:USA LWB:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.